Evofem Biosciences, Inc. Common Stock
EVFM
EVFM was delisted on the 10th of August, 2022.
8 hedge funds and large institutions have $9.12K invested in Evofem Biosciences, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 38 closing their positions.
9,350% more call options, than puts
Call options by funds: $189K | Put options by funds: $2K
82% less funds holding
Funds holding: 44 → 8 (-36)
95% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 38
100% less capital invested
Capital invested by funds: $8.59M → $9.12K (-$8.58M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
+$27.7K |
| 2 |
AWM
Activest Wealth Management
Aventure,
Florida
|
+$13.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$2.92M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.2M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.47M |
| 4 |
Citigroup
New York
|
-$832K |
| 5 |
BlackRock
New York
|
-$265K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HWA
26
HCR Wealth Advisors
Los Angeles,
California
| – | -$11K | -10,011 | Closed |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| – | -$9K | -7,846 | Closed |
|
28
Osaic Holdings
Scottsdale,
Arizona
| – | -$7K | -7,566 | Closed |
|
29
Barclays
London,
United Kingdom
| – | -$5.54K | -6,000 | -93% |
|
|
SC
30
Shay Capital
New York
| – | -$3K | -2,500 | Closed |
|
|
CG
31
Cutler Group
San Francisco,
California
| – | -$1K | -1,476 | Closed |
|
32
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1K | -1,200 | Closed |
|
33
National Bank of Canada
Montreal,
Quebec, Canada
| – | -$1K | -461 | Closed |
|
|
FDCDDQ
34
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| – | -$35 | -31 | Closed |
|
EVFM Hedge Fund Activity: Q3 2022 in Review
8 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q3 2022, worth a combined $9.12K — down 100% from $8.59M a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of EVFM and 2 opened new positions — a net loss of 36 holders — while 3 trimmed existing stakes and 0 added.
The largest buyer was Clear Street, opening a new position worth an estimated $27.7K. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $2.92M sold.
- 8 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q3 2022, down from 44 in Q2 2022.
- Funds reported $9.12K of Evofem Biosciences, Inc. Common Stock stock for Q3 2022, down 100% quarter-over-quarter.
- 2 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q3 2022 and 38 closed out, a net change of -36 holders.
- The largest Evofem Biosciences, Inc. Common Stock buyer in Q3 2022 was Clear Street, an estimated $27.7K added.
- The largest Evofem Biosciences, Inc. Common Stock seller in Q3 2022 was Baker Bros. Advisors, an estimated $2.92M sold.
Based on aggregated 13F filings for Q3 2022.